Ligand Pharmaceuticals Inc. (LGND) Position Raised by SG Americas Securities LLC

SG Americas Securities LLC increased its position in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 209.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,644 shares of the biotechnology company’s stock after purchasing an additional 9,910 shares during the period. SG Americas Securities LLC owned 0.07% of Ligand Pharmaceuticals worth $1,987,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in Ligand Pharmaceuticals by 2.5% in the third quarter. BlackRock Inc. now owns 3,346,406 shares of the biotechnology company’s stock worth $918,554,000 after acquiring an additional 81,432 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Ligand Pharmaceuticals by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,090,137 shares of the biotechnology company’s stock valued at $573,721,000 after acquiring an additional 66,789 shares during the period. Vanguard Group Inc increased its holdings in shares of Ligand Pharmaceuticals by 3.3% in the 3rd quarter. Vanguard Group Inc now owns 2,090,137 shares of the biotechnology company’s stock valued at $573,721,000 after acquiring an additional 66,789 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Ligand Pharmaceuticals by 44.1% in the 3rd quarter. Renaissance Technologies LLC now owns 754,219 shares of the biotechnology company’s stock valued at $207,026,000 after acquiring an additional 230,725 shares during the period. Finally, Conestoga Capital Advisors LLC increased its holdings in shares of Ligand Pharmaceuticals by 12.8% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 566,223 shares of the biotechnology company’s stock valued at $155,423,000 after acquiring an additional 64,329 shares during the period.

NASDAQ:LGND opened at $119.76 on Wednesday. Ligand Pharmaceuticals Inc. has a 1-year low of $98.56 and a 1-year high of $278.62. The company has a debt-to-equity ratio of 1.09, a quick ratio of 10.50 and a current ratio of 10.59. The firm has a market capitalization of $2.55 billion, a P/E ratio of 19.07, a PEG ratio of 1.17 and a beta of 1.40.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings data on Thursday, February 7th. The biotechnology company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.48. Ligand Pharmaceuticals had a net margin of 57.00% and a return on equity of 26.00%. The firm had revenue of $59.59 million for the quarter, compared to analyst estimates of $52.58 million. During the same period last year, the firm posted $1.31 EPS. Ligand Pharmaceuticals’s quarterly revenue was up 18.1% on a year-over-year basis. Analysts forecast that Ligand Pharmaceuticals Inc. will post 4.88 earnings per share for the current fiscal year.

A number of brokerages have recently commented on LGND. Zacks Investment Research raised shares of Ligand Pharmaceuticals from a “hold” rating to a “buy” rating and set a $126.00 target price on the stock in a report on Wednesday, January 23rd. ValuEngine cut shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 15th. TheStreet cut shares of Ligand Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Wednesday, January 2nd. HC Wainwright set a $281.00 target price on shares of Ligand Pharmaceuticals and gave the company a “buy” rating in a report on Monday, November 19th. Finally, Roth Capital upgraded shares of Ligand Pharmaceuticals from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $250.00 to $195.00 in a research report on Monday, October 29th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Ligand Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $238.00.

TRADEMARK VIOLATION NOTICE: “Ligand Pharmaceuticals Inc. (LGND) Position Raised by SG Americas Securities LLC” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2019/02/13/ligand-pharmaceuticals-inc-lgnd-position-raised-by-sg-americas-securities-llc.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Recommended Story: Preferred Stock

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit